Physician profile
Benjamin Downie
NPI 1477765550
$13,931.53
in general payments reported to CMS, 2019-2025
81 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $2,090 · 2021: $2,043 · 2022: $3,084 · 2023: $3,396 · 2024: $719 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.95 |
| Education | $185.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,127.09 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Janssen Biotech, INC. | $1,041.43 | 2019-2024 | Tecvayli, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $876.52 | 2019-2025 | Kisqali |
| Merck Sharp & Dohme LLC | $755.35 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Amgen INC. | $679.83 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Celgene Corporation | $598.57 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $550.58 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Genzyme Corporation | $528.11 | 2019-2023 | |
| Pfizer INC. | $458.67 | 2019-2025 | |
| Puma Biotechnology, INC. | $406.18 | 2019-2024 | |
| Astellas Pharma US INC | $383.26 | 2019-2024 | Xospata, Xtandi, Padcev |
| Lilly USA, LLC | $374.48 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $345.77 | 2019-2023 | Jakafi, Monjuvi |
| Genentech USA, INC. | $333.66 | 2019-2024 | Venclexta, Polivy, Lunsumio |
| Bayer Healthcare Pharmaceuticals INC. | $295.90 | 2019-2025 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Downie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.